Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | EED | O75530 | 2/20 | 0.49 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.49 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.49 |
| ▸ | RBBP7 | Q16576 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2594899 | 0.86 | EZH2 (0.52) | EZH2BRD4EEDRBBP4SUZ12 | |
| SCHEMBL12180071 | 0.83 | EZH2 (0.65) | EZH2BRD4EEDRBBP4SUZ12 | |
| SCHEMBL2594805 | 0.83 | EZH2 (0.65) | EZH2BRD4EEDRBBP4SUZ12 | |
| SCHEMBL12180078 | 0.82 | EZH2 (0.57) | EZH2BRD4EEDRBBP4SUZ12 | |
| SCHEMBL2588878 | 0.81 | EZH2 (0.67) | EZH2BRD4EEDRBBP4SUZ12 | |
| SCHEMBL14717619 | 0.81 | EZH2 (0.62) | EZH2BRD4EEDRBBP4SUZ12 | |
| SCHEMBL20334119 | 0.81 | EZH2 (0.68) | EZH2BRD4 | |
| SCHEMBL20317425 | 0.78 | EZH2 (0.65) | EZH2BRD4 | |
| SCHEMBL19621019 | 0.78 | EZH2 (0.42) | EZH2BRD4EEDRBBP4SUZ12 | |
| SCHEMBL12180872 | 0.77 | EZH2 (0.73) | EZH2EEDRBBP4SUZ12RBBP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20160074394-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2016-03-17 | — | — | US | disclosed |
| US-20160074394-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074394-A1 | METHOD OF TREATMENT | EZH1, EZH2, SUV39H2 | EZH2 2/4885BRD4 107/4885EED 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.